Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
F 10.83 1.64% 0.18
NVAX closed down 5.67 percent on Monday, January 30, 2023, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 1.64%
Oversold Stochastic Weakness 1.64%
20 DMA Resistance Bearish -4.12%
Bollinger Band Squeeze Range Contraction -4.12%
Stochastic Reached Oversold Weakness -4.12%
BB Squeeze Started Range Contraction -4.12%
Oversold Stochastic Weakness -4.12%
20 DMA Resistance Bearish -1.41%
Outside Day Range Expansion -1.41%
Wide Bands Range Expansion -1.41%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 31 minutes ago
Possible Inside Day 31 minutes ago
Down 1% about 4 hours ago
Up 2% about 5 hours ago
Up 1% about 5 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Novavax, Inc. Description

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Infectious Diseases Clinical Development Influenza Vaccines Coronavirus Vaccination Influenza Vaccine Rabies Seasonal Influenza

Is NVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 101.39
52 Week Low 8.75
Average Volume 7,090,568
200-Day Moving Average 34.05
50-Day Moving Average 13.65
20-Day Moving Average 11.52
10-Day Moving Average 11.56
Average True Range 1.09
RSI 39.02
ADX 12.07
+DI 23.06
-DI 23.94
Chandelier Exit (Long, 3 ATRs) 10.43
Chandelier Exit (Short, 3 ATRs) 12.02
Upper Bollinger Bands 12.94
Lower Bollinger Band 10.09
Percent B (%b) 0.2
BandWidth 24.79
MACD Line -0.60
MACD Signal Line -0.70
MACD Histogram 0.1025
Fundamentals Value
Market Cap 677.98 Million
Num Shares 63.7 Million
EPS -8.60
Price-to-Earnings (P/E) Ratio -1.24
Price-to-Sales 30.36
Price-to-Book 77.25
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.85
Resistance 3 (R3) 11.92 11.58 11.65
Resistance 2 (R2) 11.58 11.28 11.55 11.58
Resistance 1 (R1) 11.12 11.09 10.95 11.05 11.52
Pivot Point 10.78 10.78 10.70 10.75 10.78
Support 1 (S1) 10.32 10.48 10.15 10.25 9.78
Support 2 (S2) 9.98 10.29 9.95 9.72
Support 3 (S3) 9.52 9.98 9.65
Support 4 (S4) 9.45